Sulfide-containing ionizable lipids and lipid nanoparticles comprising same

By developing sulfide-containing ionizable lipids and nanoparticles, existing drug delivery systems are solved in the body and are difficult to deliver specific in vivo, achieving efficient and stable drug delivery to liver or lung tissue.

CN119032086APending Publication Date: 2024-11-26SURGINEX CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202480001817.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-02-22
Filing Date
2024-01-12
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing drug delivery systems, such as lipid-DNA conjugates, tend to cause inflammation in the body and are difficult to specifically deliver to the target organ, resulting in side effects and inefficiency.

Method used

Develop ionizable lipids and their nanoparticles that efficiently encapsulate and stabilize the delivery of anionic drugs, especially nucleic acids, through electrostatic interactions, ensuring specific delivery of drugs to the liver or lungs.

Benefits of technology

Efficient encapsulation and stable delivery of drugs are achieved, side effects are reduced in vivo, and specificity and efficiency of drug delivery are improved, especially in liver and lung tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032086A_ABST
    Figure CN119032086A_ABST
Patent Text Reader

Abstract

The present invention relates to novel sulfide-containing ionizable lipids. When the lipid nanoparticles are generated, the ionizable lipid according to the present invention enables the drug to be efficiently encapsulated in the lipid nanoparticles and enables the drug to be stably delivered into the body by electrostatically interacting with the anionic drug, thereby improving the bioavailability of the drug. Therefore, the method can be effectively applied to the related fields such as lipid nanoparticle mediated gene therapy and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to sulfide-containing ionizable lipids, and in particular, to sulfide-containing ionizable lipids, lipid nanoparticles produced using the same, and uses thereof. Background Art

[0002] Drug delivery systems (DDS) are technologies designed to effectively deliver the necessary amount of a drug while minimizing drug side effects and maximizing effectiveness and efficacy. In particular, viral vectors have been shown to be effective as drug delivery vehicles in gene therapy; however, the use of viruses as gene delivery systems is limited due to various disadvantages such as immunogenicity, size limitations of injected DNA, and challenges in large-scale production.

[0003] Therefore, as an alternative to viral systems, methods for delivering nucleic acids into cells generally involve mixing the nucleic acid with a cationic lipid or polymer, referred to as a lipid-DNA conjugate (lipoplex) and a polymer-DNA conjugate (polyplex), respectively (Hirko et al., Curr, Med, Chem., 10, 1185-1193, 2003; Merdan et al., Adv. Drug. Deliv. Rev., 54, 715-758, 2002; Spagnou et al., Biochemistry, 43, 13348-13386, 2004). In particular, lipid-DNA conjugates are widely used at the cellular level because they bind to nucleic acids and deliver them well into cells; however, their disadvantages are that when injected locally in vivo, they often cause inflammation in vivo (Filonand and Phillips, Biochim. Biophys / Acta, 1329, 345-356, 1997), and when injected into blood vessels, they accumulate in tissues such as the lungs, liver, spleen, etc., which are the organs they mainly pass through (Ren et al., Gene Therapy. 7, 764-768, 2000). Summary of the invention

[0004] Technical issues

[0005] The present inventors have made great efforts to develop novel materials that have excellent drug encapsulation efficiency and can effectively deliver anionic drugs such as nucleic acids to target organs or cells. As a result, the inventors have completed the present disclosure by confirming the excellent drug delivery effect of the novel sulfide-containing ionizable lipids disclosed herein.

[0006] Technical Solution

[0007] An object of the present disclosure is to provide a sulfide-containing ionizable lipid having a novel structure, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0008] Another object of the present disclosure is to provide lipid nanoparticles comprising an ionizable lipid, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0009] Another object of the present disclosure is to provide a drug delivery composition, which comprises lipid nanoparticles and anionic drugs, and delivers the drugs specifically to the liver or lung.

[0010] Beneficial effects

[0011] When lipid nanoparticles are produced, the sulfide-containing ionizable lipids of the present disclosure electrostatically interact with the anionic drug, thereby ensuring that the drug is efficiently encapsulated in the lipid nanoparticles and that the drug is specifically and stably delivered to the liver or lung. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 is an in vitro effect test, showing the results of measuring the luminescence intensity of the lipid nanoparticles of the present disclosure comprising ionizable lipids encapsulating mRNA in Hela, HepG2, HEK 239 and MRC-5 cells.

[0013] Figure 2 This is an in vivo effect test, showing bioluminescence photographs after intravenous injection into mice to confirm the in vivo delivery of HHES lipid nanoparticles encapsulating mRNA according to the type of ionizable lipids.

[0014] Figure 3 It is a graph confirming and comparing bioluminescence in the liver after intravenous injection into mice to confirm the in vivo delivery effect of HHES lipid nanoparticles encapsulating mRNA according to the type of ionizable lipid.

[0015] Figure 4 This is an in vivo effect test, showing a bioluminescence photograph after intramuscular injection into mice to confirm the in vivo delivery of HHES lipid nanoparticles encapsulating mRNA according to the type of ionizable lipid.

[0016] Figure 5 These are graphs confirming and comparing bioluminescence after intramuscular injection into mice to confirm the in vivo delivery effect of HHES lipid nanoparticles encapsulating mRNA according to the type of ionizable lipids.

[0017] Figure 6 It is a graph confirming the EPO protein level and MCP-1 level in the blood after intravenous injection into mice to confirm the in vivo delivery effect and initial immunogenicity of lipid nanoparticles encapsulating hEPO mRNA.

[0018] Figure 7The figure is an in vivo effect test, showing a photograph confirming bioluminescence after intravenous injection into mice, thereby confirming the in vivo delivery of lipid nanoparticles encapsulating mRNA according to the ratio of DOTAP contained.

[0019] Figure 8 It is a graph confirming and comparing the bioluminescence in the liver, spleen, and lung after intravenous injection into mice to confirm the in vivo delivery effect of lipid nanoparticles encapsulating mRNA according to the ratio of DOTAP contained.

[0020] Fig. 9 It is a diagram confirming and comparing the luminescence distribution in each organ after intravenous injection into mice to confirm the in vivo delivery effect of lipid nanoparticles encapsulating mRNA according to the ratio of DOTAP contained.

[0021] Best Mode

[0022] Detailed description is as follows. Meanwhile, the description and embodiment disclosed in the present disclosure may also be applied to other descriptions and embodiments. In other words, all combinations of the various elements disclosed in the present disclosure fall within the scope of the present disclosure. In addition, it is not considered that the scope of the present disclosure is limited by the detailed description provided below.

[0023] As a result of the research and efforts made by the inventors to achieve the above-mentioned purpose, they have completed a sulfide-containing ionizable lipid represented by the following Chemical Formula 1 and a lipid nanoparticle comprising the ionizable lipid. In addition, it has been confirmed that the lipid nanoparticles stably and effectively deliver drugs (e.g., nucleic acids) to the liver or lungs.

[0024] Sulfide-containing ionizable lipids

[0025] In order to achieve the above-mentioned object, one aspect of the present disclosure relates to an ionizable lipid represented by the following Chemical Formula 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0026] [Chemical formula 1]

[0027]

[0028] In chemical formula 1,

[0029] A is

[0030] R1 and R2 are each independently selected from -H, -C 1-6 Alkyl, -C 1-6 Alkyl -NR3R4 and -C 2-12 Alkyl-(C=O)-Y-(CH2) x SC 4-12 Any of the alkyl groups,

[0031] R3 and R4 are each independently -C 2-8 alkyl,

[0032] R5 is -C 2-12 Alkyl-(C=O)-Y-(CH2) x SC 4-12 alkyl,

[0033] Y is -O- or NR6,

[0034] R6 is -H or -C 1-3 alkyl,

[0035] m is an integer from 0 to 3,

[0036] n is independently an integer from 2 to 7,

[0037] x is an integer from 1 to 3, and

[0038] p is an integer from 0 to 2.

[0039] The present disclosure is not limited thereto, but in the compound represented by Chemical Formula 1, specifically, in Chemical Formula 1,

[0040] A can be

[0041] R5 can be -C 2-12 Alkyl-(C=O)-Y-(CH2) x SC 4-12 alkyl,

[0042] Y can be -O-,

[0043] m can be an integer from 0 to 3,

[0044] n can independently be an integer from 2 to 7,

[0045] x can be an integer from 1 to 3, and

[0046] p can be 1.

[0047] In addition, according to a detailed example of the present disclosure, the compound represented by Chemical Formula 1 may include at least any one selected from the compounds described in Table 1 below.

[0048] Table 1

[0049]

[0050] In this disclosure, unless otherwise specified, the term "alkyl" refers to a linear or branched acyclic saturated hydrocarbon. For example, "C 1-6The term "alkyl" may refer to an alkyl group containing 1 to 6 carbon atoms. Even in the case where a simple substituent is added to the alkyl structure of the present disclosure, as long as it has the same effect as the ionizable lipid of the present disclosure, it is also included in the scope of the present disclosure to the same extent.

[0051] In the present disclosure, "ionizable lipid" refers to an amine-containing lipid that can be easily protonated, also known as a lipidoid, for example, a lipid whose charge state changes depending on the surrounding pH. It ensures that the drug is efficiently encapsulated in the lipid nanoparticles through electrostatic interactions with anionic drugs and helps to form the structure of the lipid nanoparticles. The ionizable lipid of the present disclosure is characterized in that a sulfide-containing alkyl chain is bound to an amine-containing head. Specifically, the ionizable lipid can be a compound having properties similar to those of a lipid produced by the reaction of an alkyl-sulfide and an amine containing a piperazine structure.

[0052] Ionizable lipids are ionizable compounds having lipid-like properties and allow the drug (eg, anionic drugs and / or nucleic acids) to be efficiently encapsulated within lipid nanoparticles through electrostatic interactions with the drug.

[0053] In the present disclosure, the term "stereoisomer" refers to a compound of the present disclosure that has the same chemical formula or molecular formula but is different in space. Each stereoisomer and mixtures thereof are also included within the scope of the present disclosure. Unless otherwise specified, a solid line bond (-) connected to an asymmetric carbon atom may include a wedge-shaped solid line bond. or dotted wedge key Indicates the absolute arrangement of stereocenters.

[0054] The compound of Chemical Formula 1 of the present disclosure may exist in the form of a "pharmaceutically acceptable salt". As a salt, an acid addition salt formed from a pharmaceutically acceptable free acid may be useful, but the present disclosure is not limited thereto. The term "pharmaceutically acceptable salt" of the present disclosure has a concentration that has a significant effect that is relatively non-toxic and harmless to patients, and refers to any organic or inorganic acid addition salt or base addition salt of the compound represented by Chemical Formula 1, wherein the side effects caused by the salt do not reduce the beneficial effects of the compound.

[0055] Acid addition salts can be prepared by conventional methods, for example, by dissolving the compound in an excess of aqueous acid and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. Equimolar amounts of the compound and the acid or alcohol can be heated in water and the mixture evaporated to dryness, or the precipitated salt can be filtered off by suction.

[0056] At this time, the free acid may include an organic acid and an inorganic acid, wherein the inorganic acid may include hydrochloric acid, phosphoric acid, sulfuric acid or nitric acid, and the organic acid may include methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid or hydroiodic acid, but the present disclosure is not limited thereto.

[0057] In addition, pharmaceutically acceptable metal salts can be prepared with alkali. Alkali metal salts or alkaline earth metal salts can be obtained by, for example, dissolving the compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble double salt, and then evaporating and drying the filtrate. At this time, metal salts such as sodium salts, potassium salts or calcium salts can be produced, but the disclosure is not limited thereto. In addition, the corresponding silver salt can be obtained by reacting an appropriate silver salt (such as silver nitrate) with an alkali metal or alkaline earth metal salt.

[0058] Lipid nanoparticles comprising sulfide-containing ionizable lipids

[0059] Another aspect of the present disclosure relates to a lipid nanoparticle comprising an ionizable lipid represented by Chemical Formula 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The lipid nanoparticle of the present disclosure may comprise at least one ionizable lipid represented by Chemical Formula 1. In addition, depending on the purpose, an ionizable lipid different from the present disclosure may also be included.

[0060] The lipid nanoparticles may further include at least any one selected from a helper lipid, a structural lipid, and a PEG-lipid, but the present disclosure is not limited thereto.

[0061] The helper lipid that can promote the fusion of lipid nanoparticles can be used without limitation, and can be, for example, dioleoylphosphatidylethanolamine (DOPE), distearoylphosphatidylcholine (DSPC), palmitoyloleoylphosphatidylcholine (POPC), egg phosphatidylcholine (EPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylethanolamine (DSPE), 1 ,2-dioleoyl-3-trimethylammonium-propane (DOTAP), phosphatidylethanolamine (PE), dipalmitoylphosphatidylethanolamine, 1,2-dioleoyl-sn-glycero-3-phosphate (18-PA), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine, 1,2-diacetyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16:0PE), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1,2-dioleoyl-sn-glycero-3-[phospho-L-serine] (DOPS), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-heneicosyl-sn-glycero-phosphocholine (DUPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16Lyso PC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine, sphingomyelin or a mixture thereof.

[0062] In the present disclosure, PEG-lipid refers to the conjugated form of lipid and PEG, and refers to the lipid combined with the hydrophilic polymer polyethylene glycol polymer. PEG-lipid contributes to the particle stability of the nanoparticles in serum in the lipid nanoparticles, and prevents the aggregation between the nanoparticles. In addition, PEG-lipid protects nucleic acids from the influence of degradative enzymes, thereby enhancing the stability of nucleic acids in vivo, and increases the half-life of the medicine encapsulated in the nanoparticles. PEG-lipid can be, for example, PEG-ceramide, PEG-DMG, PEG-c-DOMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, PEG-DSPE or its mixture, but the present disclosure is not limited thereto.

[0063] The structural lipid maintains the particle shape in the lipid nanoparticles and is dispersed in the core and surface of the nanoparticles to improve the stability of the nanoparticles. The structural lipid can be cholesterol, cholestenol, spinasterol, fecosterol, sitosterol, ergosterol, ergostenol, campesterol, stigmasterol, brassicasterol, tomatine, ursolic acid, alpha-tocopherol or a mixture thereof, but the disclosure is not limited thereto.

[0064] As a specific example, when the ionizable lipid, helper lipid, structural lipid and PEG-lipid of the present disclosure are mixed to produce lipid nanoparticles, the molar ratio of ionizable lipid: helper lipid: structural lipid: PEG-lipid can be 10 to 40: 10 to 70: 40 to 70: 1 to 5. In addition, the molar ratio can be 15 to 35: 10 to 30: 45 to 65: 1 to 4 or 20 to 30: 15 to 25: 50 to 60: 1 to 3, but the present disclosure is not limited thereto.

[0065] The lipid nanoparticles of the present invention show positive charge under acidic pH conditions, therefore, through electrostatic interaction with therapeutic agents (e.g., nucleic acids and anionic drugs showing negative charge), it is easy to form complexes with drugs, thereby efficiently encapsulating anionic drugs, and can be used as compositions for intracellular or in vivo drug delivery. Therefore, the lipid nanoparticles of the present invention can be used not only for delivering nucleic acids, but also for delivering all types of drugs with anionic properties. In other words, the lipid nanoparticles of the present invention can eventually be produced in a form (encapsulated form) further comprising anionic drugs.

[0066] In the present disclosure, the term "encapsulation" refers to encapsulating a delivery substance to surround it and allow it to effectively enter the body, and "drug encapsulation efficiency" refers to the amount of drug encapsulated in lipid nanoparticles relative to the total amount of drug used for production.

[0067] The anionic drug may be a nucleic acid, a low molecular weight compound, a peptide, a protein, a protein-nucleic acid structure, or an anionic biopolymer-drug conjugate, but the present disclosure is not limited thereto as long as it can be stably and effectively delivered by forming lipid nanoparticles with the ionizable lipid of the present disclosure.

[0068] In the present disclosure, the nucleic acid can be small interfering ribonucleic acid (siRNA), ribosomal ribonucleic acid (rRNA), deoxyribonucleic acid (DNA), complementary deoxyribonucleic acid (cDNA), aptamer, messenger ribonucleic acid (mRNA), transfer ribonucleic acid (tRNA), sgRNA, antisense oligonucleotide, shRNA, miRNA, ribozyme, PNA, DNA enzyme or a mixture thereof, but the present disclosure is not limited thereto.

[0069] The total lipid / nucleic acid weight ratio in the lipid nanoparticle may be 1 to 20, specifically, 5 to 15, more specifically, 7 to 12, but the present disclosure is not limited thereto.

[0070] In the present disclosure, the diameter of the lipid nanoparticle may be, for example, 40 nm to 150 nm, specifically, 50 nm to 14 nm, more specifically, 60 nm to 130 nm, but the present disclosure is not limited thereto.

[0071] In another aspect of the present disclosure, the lipid nanoparticles may further include 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) as a helper lipid.

[0072] As a specific example, when the ionizable lipid, DOTAP, structural lipid and PEG-lipid of the present disclosure are mixed to produce lipid nanoparticles, DOTAP can be included in the total lipid of lipid nanoparticles in an amount of 10 mol % to 70 mol %. Specifically, the molar ratio of ionizable lipid: DOTAP: structural lipid: PEG-lipid can be 10 to 40: 10 to 70: 1 to 70: 1 to 5. In addition, the molar ratio can be 15 to 35: 15 to 65: 5 to 65: 1 to 4 or 20 to 30: 20 to 60: 10 to 60: 1 to 3, but the present disclosure is not limited thereto.

[0073] The lipid nanoparticles including DOTAP may further include anionic drugs, and the diameter of the lipid nanoparticles may be, for example, 30 nm to 100 nm, specifically, 40 nm to 100 nm, more specifically, 50 nm to 90 nm, but the present disclosure is not limited thereto.

[0074] Drug delivery and pharmaceutical compositions comprising lipid nanoparticles

[0075] Another aspect of the present disclosure relates to a drug delivery composition comprising the anionic drug-containing lipid nanoparticles according to the present disclosure.

[0076] Another aspect of the present disclosure relates to a pharmaceutical composition comprising the anionic drug-containing lipid nanoparticles according to the present disclosure as an active ingredient.

[0077] The lipid nanoparticles and the anionic drug are each as described above.

[0078] The lipid nanoparticles of the present disclosure form stable complexes with anionic drugs such as nucleic acids, and show low cytotoxicity and effective cell absorption, so anionic drugs can be effectively delivered. Therefore, according to the type of anionic drugs used and the type of nucleic acids, lipid nanoparticles have preventive or therapeutic effects on related diseases, and have unlimited potential for use as drug delivery compositions. In addition, lipid nanoparticles can be specifically delivered to the liver or lungs after administration, so the desired tissue can be targeted according to the purpose.

[0079] In the present disclosure, the term "therapeutic" refers to interventions used to change the natural course of individuals or cells suffering from a disease, which can be performed during the development of a pathological condition, or as a preventive measure. The desired therapeutic effects include preventing the onset or recurrence of the disease, alleviating symptoms, alleviating all direct or indirect pathological consequences of the disease, preventing progression, slowing the rate of disease progression, alleviating or alleviating the disease state, and achieving relief or improved prognosis. In particular, in the present disclosure, they include all effects of improving the course of the disease by administering lipid nanoparticles, which lipid nanoparticles contain ionizable lipids containing sulfides, their stereoisomers or pharmaceutically acceptable salts thereof, and anionic drugs as active ingredients. In addition, the term "preventive" refers to all actions that inhibit or delay the onset of the disease by administering lipid nanoparticles. When the lipid nanoparticles of the present disclosure are used for therapeutic or preventive purposes, they are administered to the subject in a therapeutically effective amount.

[0080] The term "therapeutically effective amount" used in the present disclosure refers to the effective amount of lipid nanoparticles containing anionic drugs. Specifically, "therapeutically effective amount" refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio suitable for medical treatment, and the effective dose level can be determined based on factors such as the type and severity of the entity, age, sex, disease type, drug activity, sensitivity to the drug, administration time, administration route and excretion rate, treatment duration, drugs used simultaneously, and other factors well-known in the medical field. The pharmaceutical composition of the present disclosure can be used as a single therapeutic agent or in combination with other therapeutic agents, or can be used sequentially or simultaneously with commercially available therapeutic agents. And the pharmaceutical composition can be used in a single dose or multiple doses. Taking all these factors into account, it is important to use the minimum amount that allows the maximum effect to be achieved without causing side effects, which can be easily determined by those skilled in the art. The dosage of the pharmaceutical composition of the present disclosure can be determined by experts based on various factors such as the patient's condition, age, sex and complications. The active ingredient of the composition of the present disclosure is highly safe, so it can be used with a dosage greater than or equal to the determined dosage.

[0081] The composition including lipid nanoparticles as an active ingredient may be administered orally, intramuscularly, intravenously, intraarterially, subcutaneously, intraperitoneally, via a pulmonary route, and nasally, but the present disclosure is not limited thereto.

[0082] The composition of the present disclosure may further include at least one pharmaceutically acceptable carrier for administration. Pharmaceutically acceptable carriers may include saline, sterile water, Ringer's solution, buffered saline, glucose solution, maltodextrin solution, glycerol, ethanol and one or more than one mixture thereof, and other commonly used additives, such as antioxidants, buffers and antibacterial agents, may be added if necessary. In addition, diluents, dispersants, surfactants, adhesives and lubricants may be further added to prepare injectable preparations, such as aqueous solutions, suspensions, emulsions, pills, capsules, granules or tablets. Therefore, the composition of the present disclosure may be in the form of patches, pills, capsules, granules, tablets, suppositories, etc. These preparations may be prepared using methods commonly used in preparations of the art or using methods disclosed in the literature [Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA], and may be formulated into various preparations suitable for each disease or component.

[0083] The embodiments of the present disclosure may be modified into various other forms, and the scope of the present disclosure is not limited to the embodiments described below. In addition, the embodiments of the present disclosure are provided to more completely explain the present disclosure to people with general knowledge in the relevant technical field. In addition, throughout the specification, the expression "includes / comprising" an element means that another element may be further included, rather than excluding the presence of the other element, unless otherwise stated.

[0084] Invention Mode

[0085] Hereinafter, the configuration and effects of the present disclosure will be described in detail through embodiments. The following embodiments are only used to illustrate the present disclosure, and the scope of the present disclosure is not limited by the following embodiments.

[0086] Preparation Example. Preparation of ionizable lipids containing sulfide

[0087] Reaction Scheme 1

[0088]

[0089] First, using the synthetic method of Reaction Scheme 1, bromic acid and 2-(hexylthio)ethan-1-ol were reacted in a 1:1 molar ratio to produce sulfide-containing tail groups with different alkyl chain lengths.

[0090] Reaction Scheme 2

[0091]

[0092] Next, using the synthetic method of Reaction Scheme 2, the tail group and N-(2-aminoethyl)piperazine as the head group were reacted in a molar ratio of 2.36:0.7 to synthesize a sulfide-containing ionizable lipid with a linear structure, named 244nHHES (where n is the number of carbon atoms from the head group to the ester group).

[0093] Example 1-1: Preparation of Compounds 1 to 4

[0094] Detailed examples of the sulfide-containing ionizable lipids disclosed herein are shown in Table 2 below.

[0095] Table 2

[0096]

[0097] As an example, the detailed preparation method of compound 3 (2448HHES) is as follows. 3 mmoles of 2-(hexylthio)ethane-1-ol and 3 mmoles of 8-bromooctanoic acid are added to 1 ml of dichloromethane (DCM) solvent, and 4.6 mmoles of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and 0.6 mmoles of 4-dimethylaminopyridine (DMAP) containing N,N-diisopropylcarbodiimide (DIC) are added to the mixture, and then stirred at room temperature for 18 hours. Next, the reaction product is filtered and evaporated under vacuum. The residue is purified by column chromatography, using a gradient elution of 95:5 from 100% hexane to hexane: ethyl acetate volume ratio, using a CombiFlash RF system (Teledyne Isco) with a RediSep Gold Resolution silica column. As a result, 2.36 mmol of 2-(hexylthio)ethyl 8-bromooctanoate was synthesized in a yield of 76.6% and named 8HHES.

[0098] Next, 2.36 mmoles of 8-bromooctanoic acid 2-(hexylthio)ethyl ester, 0.7 mmoles of N-(2-aminoethyl)piperazine and 0.7 mmoles of N,N-diisopropylethylamine were added to 1 ml of N,N-dimethylformamide (DMF) solvent, followed by stirring at 80°C for three days and then evaporating under vacuum. The residue was purified by column chromatography using a gradient elution from 100% DCM to DCM:MeOH:NH4OH volume ratio of 95:4.5:0.5, using a CombiFlash RF system (Teledyne Isco) with a RediSep Gold Resolution silica column. As a result, ionizable lipids were produced at a yield of 36.6%.

[0099] The remaining example compounds were prepared in a manner similar to Reaction Scheme 1 and Reaction Scheme 2.

[0100] Example 1-2. Confirmation of the synthesis of ionizable lipids containing sulfide

[0101] In order to confirm the synthesis of compounds 1 to 4 prepared in Example 1-1, MS analysis was performed. The results are shown in Table 3 below.

[0102] Table 3

[0103]

[0104] Example 2. Preparation of Lipid Nanoparticles Encapsulating Nucleic Acids

[0105] Example 2-1. Preparation of lipid nanoparticles containing helper lipid (DOPE)

[0106] The generated ionizable lipids (2446HHES to 2449HHES), cholesterol (cholesterol powder, BioReagent, suitable for cell culture, ≥99%, Sigma, Korea), DOPE (18:1 (Δ9-Cis) PE (DOPE), Avanti, USA) and C16-PEG2000 Ceramide (C16 PEG2000 Ceramide, Avanti, USA) were dissolved in ethanol at a molar ratio of 26.5:52:20:1.5. In addition, 30 μg of mRNA as an RNA therapeutic agent was diluted in 0.75 ml of sodium citrate.

[0107] The organic phase (ethanol) in which ionizable lipids, cholesterol, auxiliary lipids and lipid-PEG were dissolved and the aqueous phase (sodium acetate or sodium citrate) in which mRNA was dissolved were mixed at a flow rate of 12 ml / min by a microfluidic mixing device (Benchtop Nanoassemblr; PNI, Canada) to produce lipid nanoparticles encapsulating nucleic acids. In order to produce lipid nanoparticles encapsulating luciferase mRNA (SEQ ID NO: 1), the organic phase and the aqueous phase were mixed so that the weight ratio of mRNA: ionizable lipids was 1: 10 to produce lipid nanoparticles. Afterwards, in order to remove ethanol and match the pH of the body and the pH of the lipid nanoparticles, a 3500 MWCO dialysis cassette was used to dialyze for 16 hours with phosphate buffered saline (PBS).

[0108] Example 2-2. Preparation of lipid nanoparticles containing helper lipids (DOTAP)

[0109] The ionizable lipid (2448HHES): DOTAP (1,2-dioleoyl-3-trimethylammonium, Avanti, USA): cholesterol: lipid-PEG (C16-PEG2000 ceramide) was dissolved in ethanol at a molar ratio of 26.5:20 to 60:12 to 52:1.5, and the organic phase and the aqueous phase were mixed so that the weight ratio of mRNA: ionizable lipid was 1:10 to produce lipid nanoparticles (Table 4). In order to remove ethanol and match the pH of the body and the pH of the lipid nanoparticles, dialysis was performed with PBS using a 3500 MWCO dialysis cassette for 16 hours.

[0110] Table 4

[0111]

[0112] Experimental Example 1. Confirmation of the physicochemical properties of lipid nanoparticles

[0113] Experimental Example 1-1. Measurement of drug encapsulation efficiency

[0114] Ribogreen analysis (Quant-iT TM RNA, Invitrogen) measured the drug encapsulation rate (encapsulation efficiency, %) of each lipid nanoparticle that encapsulated mRNA as a nucleic acid drug. The lipid nanoparticles were diluted with 50 μl of 1xTE buffer so that the final concentration of mRNA in the 96-well plate was 4 μg / ml to 7 μg / ml. For the group not treated with Triton-X (Triton-X LNP(-)), 50 μl of 1xTE buffer was added, and for the group treated with Triton-X (Triton-X LNP(+)), 50 μl of 2% Triton-X buffer was added. After incubation at 37°C for 10 minutes, Triton-X was used to decompose the lipid nanoparticles to release the encapsulated nucleic acid. Thereafter, 100 μl of Ribogreen reagent was added to each well. The wavelength bandwidth (excitation: 485 nm, emission: 528 nm) was used. The fluorescence intensity (FL) of Triton LNP(-) and Triton LNP(+) was measured by 200PRO NanoQuant (Tecan), and the drug encapsulation rate (encapsulation efficiency, %) was calculated according to the following equation 1.

[0115] Equation 1

[0116] Drug encapsulation efficiency (%) = (fluorescence of Triton LNP (+) - fluorescence of Triton LNP (-)) / (fluorescence of Triton LNP (+)) × 100

[0117] Table 5

[0118]

[0119] As confirmed in Table 5, it was confirmed that the lipid nanoparticles according to the present disclosure can efficiently encapsulate drugs.

[0120] Experimental Example 1-2. Measurement of particle size

[0121] The size of the lipid nanoparticles encapsulating nucleic acids produced was measured. The RNA (luciferase mRNA) contained in each lipid nanoparticle produced in Example 2 was diluted to a concentration of 1 μg / ml using PBS, and the diameter and polydispersity index (PDI) of the LNPs were measured using dynamic light scattering (DLS) using a Malvern Zetasizer Nano (Malverm Instruments, UK).

[0122] The corresponding result values ​​are as follows (Table 6).

[0123] Table 6

[0124] LNP Diameter(nm) PDI 2447HHES 69.58 0.249 2448HHES 60.40 0.192 2449HHES 49.26 0.247

[0125] Experimental Example 2. Confirmation of the in vitro effect of lipid nanoparticles encapsulating nucleic acids

[0126] To confirm the in vitro effects of nucleic acid-encapsulated lipid nanoparticles, screening was performed using lipid nanoparticles synthesized with various tail groups.

[0127] The test was performed by delivering luciferase mRNA to HeLa, HepG2, HEK 293 and MRC-5 cells using lipid nanoparticles (Compounds 1 to 4), each synthesized with various tail groups, followed by measuring the luminescence intensity to confirm the expression of the gene.

[0128] Specifically, one day before transfection of cells with lipid nanoparticles, HeLa, HepG2, HEK 293, and MRC-5 cells (from the Korean Cell Line Bank) were cultured at 0.01×10 6 The density of cells / well was distributed into white (96-well) plates and cultured in DMEM medium (SH30022, Hyclone, USA) at 37°C and 0.5% to 3% CO2. The cells were treated with lipid nanoparticles encapsulating luciferase mRNA at a dose of 25 ng / well based on the mRNA contained in the lipid nanoparticles. After 24 hours, 100 μl / well of Bright-Glo TM The cells were treated with luciferase assay solution (Promega, USA) and then left at room temperature for 10 minutes. The luminescence intensity of the lysed cells was then measured using an Infinite M200 luminometer (Tecan, USA).

[0129] like Figure 1 As confirmed in , it was confirmed that the luminescence intensity was significantly increased in all lipid nanoparticles compared with SM-102 as a positive control group.

[0130] Experimental Example 3. Confirmation of the in vivo effect of lipid nanoparticles

[0131] Experimental Example 3-1. Effect of luciferase mRNA encapsulated in lipid nanoparticles

[0132] Generate lipid nanoparticles encapsulating luciferase mRNA, and each nanoparticle is dialyzed in PBS for 16 hours to remove ethanol. The lipid nanoparticles encapsulating mRNA are injected intravenously or intramuscularly into C57BL / 6 7-week-old female mice (Orient bio) based on the dosage of mRNA 0.1mg / kg contained in the lipid nanoparticles, then, after 6 hours, 0.25mg / kg of luciferin is administered intraperitoneally to confirm bioluminescence using IVIS (PerkinElmer, USA) equipment. The mice encapsulating the lipid nanoparticles of luciferase mRNA are killed, and their organs are collected, and the biodistribution of lipid particles in each organ is confirmed using IVIS equipment.

[0133] like Figure 2 and Figure 3 As shown, as a result of intravenous injection, it was confirmed by whole-body imaging and ex vivo organ imaging that lipid nanoparticles encapsulating luciferase mRNA and containing HHES ionizable lipids exhibited high luminescence intensity specifically in the liver.

[0134] Furthermore, as a result of intramuscular injection, it was confirmed that lipid nanoparticles encapsulating luciferase mRNA and containing HHES ionizable lipids emitted light at the injection site. Figure 4 and Figure 5 )

[0135] Experimental Example 3-2. Effect of lipid nanoparticles encapsulating hEPO mRNA

[0136] Lipid nanoparticles loaded with hEPO mRNA (SEQ ID NO: 2) were administered to mice at a mRNA dose of 0.5 mg / kg by intravenous injection. Blood was collected 6 hours after injection, and serum was separated from the blood. The levels of hEPO and MCP-1 were confirmed using hEPO ELISA kit (DEP00; R&D systems, Minneapolis, MN, USA) and MCP-1 ELISA kit (BMS281; ThermoFisher, Waltham, MA, USA).

[0137] Results, such as Figure 6 As shown, it was confirmed that the lipid nanoparticles containing ionizable lipids of the present invention showed significantly higher levels of EPO protein in the blood compared with MC-3, and showed significantly lower levels of MCP-1 compared with SM-102. MCP-1 is an indicator of the initial immunogenicity of lipid nanoparticles, and it was confirmed that the ionizable lipid-containing lipid nanoparticles of the present invention have significantly lower initial immunogenicity than SM-102.

[0138] Experimental Example 4. Confirmation of the properties and effects of lipid nanoparticles containing helper lipids (DOTAP)

[0139] Experimental Example 4-1. Confirmation of the properties of lipid nanoparticles according to the ratio of DOTAP contained

[0140] The physical and chemical properties of the lipid nanoparticles produced in Example 2-2 were confirmed and are shown in the following Table 7. Even when DOTAP was used as a helper lipid, an excellent drug encapsulation efficiency was confirmed.

[0141] Table 7

[0142] EE(%) Diameter(nm) PDI Zeta(mV) 0% DOTAP 94.5 75.4±12.5 0.092 -0.96±0.15 20% DOTAP 98.8 53.7±1.5 0.139 -2.82±0.15 40% DOTAP 99.0 61.1±3.3 0.142 1.51±0.12 60% DOTAP 98.8 59.35±6.3 0.131 4.70±0.35

[0143] Experimental Example 4-2. Confirmation of in vivo effects according to the ratio of DOTAP contained

[0144] The lipid nanoparticles encapsulating luciferase mRNA were injected intravenously into C57BL / 67 week-old female mice (Orient bio) at a dose of 0.1 mg / kg of mRNA based on the lipid nanoparticles, and then, 6 hours later, 0.25 mg / kg of luciferin was administered intraperitoneally to confirm bioluminescence by IVIS (PerkinElmer, USA) equipment. The mice to which the lipid nanoparticles encapsulating luciferase mRNA were administered were sacrificed, and their organs were collected to confirm the biodistribution of lipid particles in each organ by IVIS equipment.

[0145] As a result, whole-body imaging and ex vivo organ imaging confirmed that lipid nanoparticles encapsulating luciferase mRNA showed high luminescence intensity in the lungs ( Figure 7 ). Therefore, it was confirmed that the lipid nanoparticles comprising ionizable lipids and DOTAP of the present disclosure delivered nucleic acids specifically to the lung.

[0146] According to the above description, those skilled in the art to which the present disclosure belongs will be able to understand that the present disclosure can be implemented in other specific forms without changing its technical ideas or basic features. In this regard, it should be understood that the above embodiments are illustrative in all aspects, rather than restrictive. The scope of the present disclosure should be interpreted as including all changes or modifications derived from the meaning and scope of the claims and their equivalents, rather than from the above detailed description.

Claims

1. An ionizable lipid represented by Chemical Formula 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: [Chemical formula 1] in, A is R1 and R2 are each independently selected from -H, -C 1-6 Alkyl, -C 1-6 Alkyl -NR3R4 and -C 2-12 Alkyl-(C=O)-Y-(CH2) x SC 4-12 Any of the alkyl groups, R3 and R4 are each independently C 2-8 alkyl, R5 is -C 2-12 Alkyl-(C=O)-Y-(CH2) x SC 4-12 alkyl, Y is -O- or NR6, R6 is -H or -C 1-3 alkyl, m is an integer from 0 to 3, n is independently an integer from 2 to 7, x is an integer from 1 to 3, and p is an integer from 0 to 2.

2. The ionizable lipid according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein A is R5 is -C 2-12 Alkyl-(C=O)-Y-(CH2) x SC 4-12 alkyl, Y is -O-, m is an integer from 0 to 3, n is independently an integer from 2 to 7, x is an integer from 1 to 3, and p is 1.

3. The ionizable lipid, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 1, wherein the ionizable lipid is selected from compounds 1 to 4 shown in the following table 4. A lipid nanoparticle comprising the ionizable lipid, a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3.

5. The lipid nanoparticle according to claim 4, further comprising at least any one selected from a helper lipid, a structural lipid and a PEG-lipid.

6. The lipid nanoparticle according to claim 5, wherein the helper lipid is selected from DOPE, DSPC, POPC, EPC, DOPC, DPPC, DOPG, DPPG, DSPE, DOTAP, phosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, 1,2-dioleoyl-sn-glycero-3-phosphate, 1,2-dilinoleoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-docosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine, POPE, DOPS, At least any one of DLPC, DMPC, DUPC, 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine, 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine, 1-hexadecyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine and sphingomyelin.

7. The lipid nanoparticle according to claim 5, wherein the PEG-lipid is at least any one selected from PEG-ceramide, PEG-DMG, PEG-c-DOMG, PEG-DLPE, PEG-DMPE, PEG-DPPC and PEG-DSPE.

8. The lipid nanoparticle according to claim 5, wherein the structural lipid is at least any one selected from cholesterol, cholestenol, spinasterol, coprostanol, sitosterol, ergosterol, ergostenol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid and α-tocopherol.

9. The lipid nanoparticle of claim 5, wherein the lipid nanoparticle comprises an ionizable lipid: helper lipid: structural lipid: PEG-lipid in a molar ratio of 10 to 40: 10 to 70: 40 to 70: 0.5 to 5.

10. The lipid nanoparticle according to claim 5, further comprising an anionic drug.

11. The lipid nanoparticle of claim 10, wherein the anionic drug is at least any one selected from nucleic acids, low molecular weight compounds, peptides, proteins, protein-nucleic acid structures, and anionic biopolymer-drug conjugates.

12. The lipid nanoparticle of claim 11, wherein the nucleic acid is at least any one selected from small interfering ribonucleic acid (siRNA), ribosomal ribonucleic acid (rRNA), deoxyribonucleic acid (DNA), complementary deoxyribonucleic acid (cDNA), aptamers, messenger ribonucleic acid (mRNA), transfer ribonucleic acid (tRNA), sgRNA, antisense oligonucleotide, shRNA, miRNA, ribozyme, PNA and DNA enzyme.

13. The lipid nanoparticle of claim 12, wherein the total lipid / nucleic acid weight ratio in the lipid nanoparticle is 1 to 20.

14. The lipid nanoparticle of claim 10, wherein the average diameter of the lipid nanoparticle is 40 nm to 150 nm.

15. A drug delivery composition comprising the lipid nanoparticle according to claim 10.

16. The drug delivery composition of claim 15, wherein the drug delivery composition is delivered specifically to the liver.

17. The drug delivery composition of claim 15, wherein the lipid nanoparticles further comprise DOTAP, and the lipid nanoparticles are specifically delivered to the lung.

18. The drug delivery composition according to claim 17, wherein the DOTAP is contained in an amount of 10 mol% to 70 mol% in the total lipids of the lipid nanoparticles.

Citation Information

Cited By

  • Lipid compound as well as nanoparticles and application thereof

    CN120943786A